LLY

ELI LILLY & CO

Healthcare • USA

Apr 05 • 04:00PM ET
757.39
+24.1 (+3.29%)
Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, ... read more

Full Time Employees 43,000
Phone 317 276 2000
Website https://www.lilly.com
CEO Mr. David A. Ricks
IPO Date 1972-06-01
Sector Healthcare
Industry Drug Manufacturers - General
Address Lilly Corporate Center, Indianapolis, IN 46285
Balance Sheet
Total Cash $3,093,300,000
Total Debt $38,515,900,000
Current Ratio 1.37
Quick Ratio 0.57
Profitability
Gross Margin 81.70%
Net Margin 22.66%
ROE 70.45%
ROA 12.42%
ROIC 20.46%
Balance Sheet
Total Cash $3,093,300,000
Total Debt $38,515,900,000
Current Ratio 1.37
Quick Ratio 0.57
Profitability
Gross Margin 81.70%
Net Margin 22.66%
ROE 70.45%
ROA 12.42%
ROIC 20.46%
Name ELI LILLY & CO Sector Healthcare Currency USD Relative Volume 1.43 Market Cap 699948
Current Ratio 1.15 Dividend / Share 5.2 EPS 11.71 Revenue 45042700000 P/S 15.5
P/E 66.1 Beta 0.75 Income 10590000000 Volume 5246335 Average Volume 3673402
Distance to 200DMA -13.55% 200 DMA 853.9 50 DMA 847.11 ROA 14.6 ROE 77.3
Distance to 50DMA -12.86% Return 1Y -4.24% Return YTD -4.21% Forward PE Qtly Growth YOY
Debt/Eq 4.54 P/B 49.3 Dividend Yield 0.7% Net Margin 23.51% Payout Ratio 44.2
Performance
52 Week Range 44.2%
Distance to 200DMA 0.17%
Day Change Percent $1.30
Performance Week $1.3
Performance Month $1.3
Performance Quarter 2024-08-15
Performance YTD $1.3
Performance Year $1.3

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $3,369,000,000
Total Debt $31,119,700,000
Current Ratio 1.27%
Quick Ratio 0.62%
Profitability
Gross Margin 81.70%
Net Margin 22.66%
ROE 70.45%
ROA 12.42%
ROIC 20.46%
Valuation
Price to Earnings 61.29
Price to Book 43.18
Price to Sales 13.89
Price to Free Cash Flow 182.17
Dividends
Payout Ratio 43.70%
Dividend Yield 0.71%
Dividend Amount $1.30
Last Dividend Pay Date 2024-08-15
Last Dividend Paid $1.3
Performance
52 Week Range 44.2%
Distance to 200DMA 0.17%
Day Change Percent $1.30
Performance Week $1.3
Performance Month $1.3
Performance Quarter 2024-08-15
Performance YTD $1.3
Performance Year $1.3
Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, ... read more

Full Time Employees 43,000
Phone 317 276 2000
Website https://www.lilly.com
CEO Mr. David A. Ricks
IPO Date 1972-06-01
Sector Healthcare
Address Lilly Corporate Center, Indianapolis, IN 46285
Histogram - Daily

Balance Sheet
Total Cash $3,369,000,000
Total Debt $31,119,700,000
Current Ratio 1.27%
Quick Ratio 0.62%
Profitability
Gross Margin 0.8090%
Net Margin 0.2050%
ROE 0.65%
ROA 0.12%
Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, ... read more

Full Time Employees 43,000
Phone 317 276 2000
Website https://www.lilly.com
CEO Mr. David A. Ricks
IPO Date 1972-06-01
Sector Healthcare
Address Lilly Corporate Center, Indianapolis, IN 46285
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript
Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Tra

Eli Lilly and Company (NYSE:LLY ) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants

2025-05-15 14:51:58 - seekingalpha.com
2 Stocks That Plummeted During President Trump's First 100 Days in Office, and Where They Could Be Headed
2 Stocks That Plummeted During President Trump's First 100 Days in Office, and W

President Donald Trump's first 100 days in office occurred between Monday, Jan. 20, and Tuesday, April 29. During this period, the S&P 500 (^GSPC 0.10%) and Nasdaq Composite (^IXIC 0.72%) dropped by 7

2025-05-15 04:55:00 - fool.com
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.

2025-05-14 09:55:47 - zacks.com
PFE vs. LLY: Which Stock Is the Better Value Option?
PFE vs. LLY: Which Stock Is the Better Value Option?

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those

2025-05-13 12:45:41 - zacks.com
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.

2025-05-13 11:18:00 - barrons.com
Why Lilly (LLY) International Revenue Trends Deserve Your Attention
Why Lilly (LLY) International Revenue Trends Deserve Your Attention

Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

2025-05-13 10:21:54 - zacks.com
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared

President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.

2025-05-13 08:40:53 - zacks.com
NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs
NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs

The executive order that Donald Trump has signed over the last 24 hours could have a significant effect on pharmaceutical companies, and as a result, we should be paying attention to this sector.

2025-05-13 08:40:10 - fxempire.com
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy

Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,

2025-05-12 18:25:11 - seekingalpha.com
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical

Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.

2025-05-12 13:21:43 - youtube.com
Drugmakers are spared worst-case drug pricing scenario for now
Drugmakers are spared worst-case drug pricing scenario for now

Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.

2025-05-12 13:14:00 - wsj.com
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Dr. Scott Gottlieb: What to expect from President Trump's executive order to low

Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.

2025-05-12 12:36:24 - youtube.com
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t

2025-05-12 12:30:03 - seekingalpha.com
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial

Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the firs

2025-05-12 10:46:51 - proactiveinvestors.com
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs

The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.

2025-05-12 10:41:06 - zacks.com
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.

2025-05-12 09:12:00 - wsj.com